Protein-targeting strategy used to develop a selective inhibitor of the E17K point mutation in the PH Domain of Akt1

Ligands that can selectively bind to proteins with single amino acid point mutations offer the potential to detect or treat an abnormal protein in the presence of the wildtype. However, it is difficult to develop a selective ligand if the point mutation is not associated with an addressable location, such as a binding pocket. Here we report an all-chemical, synthetic epitope-targeting strategy which we used to discover a 5-mer peptide with selectivity for the E17K transforming point mutation in the Pleckstrin Homology Domain of the Akt1 oncoprotein. A fragment of Akt1 containing the E17K mutation and a I19[Propargylglycine] substitution was synthesized to form an addressable synthetic epitope. Azide-presenting peptides that covalently clicked onto this alkyne-presenting epitope were selected from a library using in situ screening. One peptide exhibits a 10:1 in vitro selectivity for the oncoprotein relative to wildtype, with a similar selectivity in cells. This 5-mer peptide was expanded into a larger ligand that selectively blocks the E17K Akt1 interaction with its PIP3 substrate.

[1]  W. Marasco,et al.  Intracellular antibodies (intrabodies) for gene therapy of infectious diseases. , 1997, Annual review of microbiology.

[2]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[3]  C. Roumestand,et al.  Inhibition of Akt Kinase Activity by a Peptide Spanning the βA Strand of the Proto-oncogene TCL1* , 2004, Journal of Biological Chemistry.

[4]  B. Karger,et al.  Coumarin tags for improved analysis of peptides by MALDI-TOF MS and MS/MS. 1. Enhancement in MALDI MS signal intensities. , 2004, Analytical chemistry.

[5]  Thomas Kodadek,et al.  Synthetic molecules as antibody replacements. , 2004, Accounts of chemical research.

[6]  J. Testa,et al.  AKT signaling in normal and malignant cells , 2005, Oncogene.

[7]  M. Morris,et al.  Cell-penetrating peptides: tools for intracellular delivery of therapeutics , 2005, Cellular and Molecular Life Sciences CMLS.

[8]  Spyro Mousses,et al.  A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.

[9]  M. Beyermann,et al.  Solid-phase peptide synthesis: from standard procedures to the synthesis of difficult sequences , 2007, Nature Protocols.

[10]  Lei Du-Cuny,et al.  Discovery of a novel class of AKT pleckstrin homology domain inhibitors , 2008, Molecular Cancer Therapeutics.

[11]  M. Loda,et al.  Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer , 2009, Clinical Cancer Research.

[12]  Jason E Hein,et al.  Iterative in situ click chemistry creates antibody-like protein-capture agents. , 2009, Angewandte Chemie.

[13]  I. Hamachi,et al.  Ligand-directed tosyl chemistry for protein labeling in vivo. , 2009, Nature chemical biology.

[14]  H. Zentgraf,et al.  Monoclonal antibody specific for IDH1 R132H mutation , 2009, Acta Neuropathologica.

[15]  J. Heath,et al.  Accurate MALDI-TOF/TOF sequencing of one-bead-one-compound peptide libraries with application to the identification of multiligand protein affinity agents using in situ click chemistry screening. , 2010, Analytical chemistry.

[16]  James F Rusling,et al.  Measurement of biomarker proteins for point-of-care early detection and monitoring of cancer. , 2010, The Analyst.

[17]  H. Zentgraf,et al.  Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody , 2011, Acta Neuropathologica.

[18]  Andrea L J Marschall,et al.  Targeting antibodies to the cytoplasm , 2011, mAbs.

[19]  Kenneth W Dunn,et al.  A practical guide to evaluating colocalization in biological microscopy. , 2011, American journal of physiology. Cell physiology.

[20]  J. Heath,et al.  Iterative in situ click chemistry assembles a branched capture agent and allosteric inhibitor for Akt1. , 2011, Journal of the American Chemical Society.

[21]  G. Verdine,et al.  Stapled peptides for intracellular drug targets. , 2012, Methods in enzymology.

[22]  J. Heath,et al.  A chemical epitope-targeting strategy for protein capture agents: the serine 474 epitope of the kinase Akt2. , 2013, Angewandte Chemie.

[23]  J. Heath,et al.  In situ click chemistry: from small molecule discovery to synthetic antibodies. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[24]  P. Jänne,et al.  The quest to overcome resistance to EGFR-targeted therapies in cancer , 2013, Nature Medicine.

[25]  Amethist S. Finch,et al.  A chemically synthesized capture agent enables the selective, sensitive, and robust electrochemical detection of anthrax protective antigen. , 2013, ACS nano.

[26]  Jocelyn T. Kim,et al.  A Cocktail of Thermally Stable, Chemically Synthesized Capture Agents for the Efficient Detection of Anti-Gp41 Antibodies from Human Sera , 2013, PloS one.

[27]  Juswinder Singh,et al.  In Vitro and In Vivo Characterization of Irreversible Mutant-Selective EGFR Inhibitors That Are Wild-Type Sparing , 2014, Molecular Cancer Therapeutics.